New drug combo aims to fight tough pancreatic cancer

NCT ID NCT05257993

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called JPI-547, taken as a pill, together with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination helps shrink tumors or slow the disease. About 71 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JPI-547 (a dual PARP/Tankyrase inhibitor) combined with chemotherapy (mFOLFIRINOX or gemcitabine-nab-paclitaxel)
What this could lead to
If successful, this could lead to a new combination treatment option for advanced pancreatic cancer, potentially improving tumor control and survival.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

    Contact

  • Seoul National University Bundang Hospital

    RECRUITING

    Gyeonggi-do, South Korea

    Contact

  • Seoul national university hospital

    RECRUITING

    Seoul, South Korea

    Contact

  • Severance Hospital

    RECRUITING

    Seoul, South Korea

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.